Spinal Muscular Atrophy Market Set to hit Huge Growth in United States and Japan (2026-2033)

DataM Intelligence has published its latest research report, "Spinal Muscular Atrophy Market Size 2026." The report provides comprehensive analysis of market dynamics, including regional growth patterns, segment-wise performance, CAGR forecasts, competitive positioning, and revenue trends across key industry participants. It also examines the major factors influencing market expansion, emerging business opportunities, and strategic developments. Designed to support informed business planning, the study delivers a clear assessment of market value, volume, and future growth prospects within the global Spinal Muscular Atrophy market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/spinal-muscular-atrophy-market?kb

United States: Recent Industry Developments

✅ May 2026: Scholar Rock announced FDA acceptance of the Biologics License Application (BLA) for apitegromab to treat spinal muscular atrophy (SMA), with a U.S. launch planned following regulatory approval.

✅ March 2026: Biogen received U.S. FDA approval for the high-dose regimen of SPINRAZA® (nusinersen), providing a new treatment option for patients with spinal muscular atrophy.

✅ March 2026: Scholar Rock resubmitted its apitegromab BLA after aligning with FDA guidance and incorporating two U.S. fill-finish manufacturing facilities to support commercialization.

✅ January 2026: Scholar Rock outlined its 2026 strategy, prioritizing regulatory approval and commercial launch of apitegromab while advancing additional SMA development programs.

Ready to get in the Spinal Muscular Atrophy Market? connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/spinal-muscular-atrophy-market?kb

List of Key Players 2026:

Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, PTC Therapeutics, Chugai Pharmaceutical, and Eisai Co., Ltd

Growth Forecast Projected 2026:

The Global Spinal Muscular Atrophy Market is projected to witness significant growth during the forecast period from 2026 to 2033. The market maintained steady momentum in 2025, and increasing strategic investments, technological advancements, and expansion initiatives by leading companies are expected to accelerate market growth throughout the forecast period.

Key Developments 2026:

In July 2026, Novartis received European Commission approval for Itvisma®, a one-time gene replacement therapy for children, adolescents, and adults with 5q Spinal Muscular Atrophy (SMA), expanding treatment access across the European Union.

In June 2026, Biogen Inc. announced that the U.S. FDA granted Breakthrough Therapy Designation to salanersen, its investigational once-yearly antisense oligonucleotide therapy for Spinal Muscular Atrophy, supported by encouraging Phase 1b clinical data.

In June 2026, Scholar Rock announced new clinical data presentations for apitegromab at the 2026 Cure SMA Research & Clinical Care Meeting, highlighting progress from its Phase 3 SAPPHIRE trial and Phase 2 FORGE study in patients with Spinal Muscular Atrophy.

In May 2026, Scholar Rock announced that the U.S. FDA accepted the Biologics License Application (BLA) for apitegromab, setting a September 2026 PDUFA date for its potential use in treating children and adults with Spinal Muscular Atrophy.

In January 2026, Biogen Inc. received European Commission approval for the high-dose regimen of SPINRAZA® (nusinersen) for the treatment of 5q Spinal Muscular Atrophy, based on positive results from the DEVOTE clinical study.

How Our Market Research Process Works:

The global Spinal Muscular Atrophy Market research report is built on a robust blend of primary and secondary research methodologies. The study provides detailed analysis of key market influences, including regulatory frameworks, shifting industry dynamics, competitive landscapes, and historical market performance. It further examines technological progress, emerging innovations, and developments across adjacent sectors. Additionally, the report evaluates growth potential, market uncertainties, operational challenges, and emerging opportunities that are expected to shape the future trajectory of the global Spinal Muscular Atrophy market.

Latest FDA approvals by Spinal Muscular Atrophy 2026:

High-dose Spinraza was approved by the FDA in March 2026 for spinal muscular atrophy, with a faster loading schedule than the original regimen.biospace

Cure SMA also noted the FDA's 2025 approval of Itvisma, extending gene-therapy options for SMA patients 2 years and older.fda

These approvals reinforce the continued shift toward both gene replacement and optimized antisense dosing in SMA care.

Request Strategic Market Customization: https://datamintelligence.com/customize/spinal-muscular-atrophy-market?kb

Japan: Recent Industry Developments

✅ March 2026: Biogen confirmed that the newly approved high-dose SPINRAZA® regimen is also authorized in Japan, expanding treatment options for SMA patients.

✅ March 2026: Biogen presented new long-term clinical data on high-dose SPINRAZA and investigational salanersen at international SMA scientific conferences, supporting future treatment advancements relevant to Japan.

✅ January 2026: Novartis continued expanding access to its next-generation SMA gene therapy Itvisma following regulatory approvals, strengthening its global SMA portfolio, including key Asia-Pacific markets.

✅ January 2026: Roche continued supporting the adoption of EVRYSDI® (risdiplam) through ongoing post-marketing evidence generation and patient access initiatives across Japan for spinal muscular atrophy treatment.

Major Focused Key Segmentations 2026:

By Type: SMA type 0 (Congenital SMA), SMA type 1 (Severe SMA), SMA type 2 (Intermediate SMA), SMA type 3 (Mild), SMA type 4 (Adult)

By Treatment: Disease-modifying Therapy, Gene Replacement Therapy

By Route of Administration: Injectables, Oral

Regional Growth Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

We Provide Benefits of the Report:

Chapter 1: Establishes the report framework by outlining market scope, key segments by region, product type, and application. It provides a comprehensive overview of current market size, growth outlook, and projected industry development across short-, medium-, and long-term horizons.

Chapter 2: Highlights the most influential market findings, examining the major trends, opportunities, and forces driving industry transformation and future growth.

Chapter 3: Delivers an in-depth assessment of the competitive environment, including market share analysis, strategic developments, partnerships, and mergers & acquisitions influencing industry dynamics.

Chapter 4: Profiles leading market participants with detailed insights into financial performance, product offerings, business strategies, profitability, and significant corporate developments.

Chapters 5 & 6: Provide comprehensive revenue analysis at regional and country levels, identifying market size, growth trends, investment hotspots, and emerging expansion opportunities worldwide.

Chapter 7: Examines the market by product category, uncovering segment-level performance trends and highlighting promising areas for future growth and investment.

Chapter 8: Evaluates the market by application, analyzing demand patterns across end-use industries and identifying sectors expected to generate substantial growth opportunities.

Chapter 9: Offers a detailed overview of the industry value chain, covering upstream suppliers, downstream consumers, and key processes that influence market development.

Chapter 10: Concludes with a strategic summary of the report's most important findings, market opportunities, and actionable insights shaping the industry's future direction.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=spinal-muscular-atrophy-market?kb

Latest Clinical Trials by Spinal Muscular Atrophy 2026:

Biogen's salanersen received FDA Breakthrough Therapy Designation in June 2026, supporting ongoing late-stage development in SMA.curesma

NMD Pharma's SYNAPSE-SMA Phase 2 trial completed participant treatment in June 2026, marking a key trial milestone.curesma

The SMA pipeline remains active, with more than 18 companies and 20+ pipeline drugs in development as of June 2026

FAQ

Q1: What is the current valuation of the Spinal Muscular Atrophy Market?

A: The Spinal Muscular Atrophy Market was valued at US$5.13 billion in 2025 and is anticipated to reach US$23.37 billion by 2033, reflecting strong growth potential across key industry segments.

Q2: What is the projected growth rate of the Spinal Muscular Atrophy Market?

A: The Spinal Muscular Atrophy Market is expected to expand at a CAGR of 16.5% from 2026 to 2033, driven by increasing demand, evolving consumer preferences, and expanding application areas.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Spinal Muscular Atrophy Market 2026: U.S., Japan, Europe, and MEA

United States

• July 2026: Novartis expanded U.S. commercialization and manufacturing investments following the FDA approval of Itvisma®, broadening gene therapy access for patients aged two years and older with SMA.

Japan

• June 2026: Japanese academic hospitals and rare disease centers increased investments in SMA genetic testing and long-term patient registry programs to support earlier diagnosis and treatment monitoring.

Europe

• July 2026: Novartis invested in the European launch of Itvisma® after receiving European Commission approval, supporting market access, treatment centers, and physician education across EU countries.

Middle East & Africa

• June 2026: Gulf healthcare providers continued investments in rare disease treatment infrastructure and newborn screening initiatives to improve access to advanced SMA therapies across the region.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.